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Abstract. Previously, we studied the erythroblastic leukemia 
viral oncogene homolog (erbB) family of tyrosine kinase 
growth factor receptors in terms of protein expression, modu-
lation and activation in the 3T3-L1 cell line. In the present 
study, the presence of full-length erbB mRNAs, and splice 
or proteolytic erbB variants, was evaluated using RT-PCR. 
Epidermal growth factor receptor (EGFR)/erbB1 expression 
was confirmed. Wild-type (wt) ErbB2, human erbB2 (HER2)-
extracellular domain (ECD) and herstatin mRNA expression 
were analyzed. Restriction analysis confirmed wt expression. 
3T3-L1 cells exhibited HER2-ECD and herstatin mRNA 
expression, although at extremely low levels (compared to the 
control cell lines). ErbB3 cDNA was amplified using mouse 
mammary tumors and rat acines as positive controls. ErbB4 
was not positively identified in these cells. In conclusion, this 
study demonstrates that 3T3-L1 cells express EGFR/erbB1, 
erbB2 and erbB3, and possibly, certain erbB2 splice or proteo-
lytic variants, which are worth pursuing.
Introduction
The erythroblastic leukemia viral oncogene homolog (erbB) 
family of tyrosine kinase growth factor receptors consists of 
transmembrane proteins that dimerize in order to transduce 
their signal. This homolog includes the epidermal growth factor 
receptors (EGFRs) erbB1, erbB2, erbB3 and erbB4. These recep-
tors share a similar structure and a high degree of homology (1) 
i.e. a glycosylated extracellular binding domain, a single trans-
membrane domain and a cytoplasmic tyrosine kinase domain. 
Binding of a specific ligand to one of the erbB receptors triggers 
the formation of specific receptor homo- and heterodimers, with 
erbB2 as the preferred signaling partner (2). Signaling from 
heterodimers usually presents distinct features compared to the 
corresponding homodimers as a way of diversifying the signal 
(3). It was demonstrated that the role of erbB in cell prolifera-
tion, differentiation and survival is of extreme significance (4,5). 
ErbB2 overexpression and amplification were observed 
in a variety of human epithelial tumors and were correlated 
with an unfavourable prognosis in patients with breast and 
ovarian cancer (6). Heterodimeric receptor combinations 
containing erbB2, particularly erbB2-erbB3, exhibit superior 
signal-transducing and cell-growth stimulating capabilities 
(7-9). The evidence indicates that erbB2 confers an autocrine 
growth advantage to tumor cells.
Various growth factor receptors (VEGFR; erbB1, erbB2 or 
erbB3) (10-12), cytokine receptors (IL-1β and IL-2) (13) and 
even ion channels (CFTR) (14) have soluble forms capable of 
ligand binding, frequently detected in cultured tumor cells, 
conditioned media and in biological fluids, including blood 
and urine. These soluble forms are produced by limited 
proteolysis of full membrane receptors (15-18) or by alterna-
tive splicing (10,11,19). Their transcripts codify for proteins 
that retain all, a part or nothing from the transmembrane or 
cytoplasmic domains. Their widespread presence indicates 
that these soluble forms may have important physiological 
functions, since the relative abundance of these mRNAs 
usually changes with the developmental stage of morphogen-
esis. Given that 3T3-L1 cells differentiate from preadipocytes 
(fibroblasts) to adipocytes, a mechanism of this type is to be 
expected. The occurence of these receptor isoforms in 3T3-L1 
cells may be of interest since they have not been previously 
described in adipocytes and their presence may explain the 
modulation that erbB2 and EGFR exhibit at the protein level 
during and after the differentiation induction phase (20).
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Previously, we studied erbB1/EGFR, erbB2, erbB3 and 
erbB4 as well as ligands, heregulin and EGF, in terms of 
expression, activation and modulation during the adipogenic 
process in 3T3-L1 cells (20,21). In this study, the presence of 
full-length erbB mRNAs and, of splice or proteolytic variants 
were examined using RT-PCR. 
Materials and methods
Cell culture. Swiss 3T3-L1 preadipocytes (fibroblasts, embryo, 
mouse: ATCC CCL 92.1), purchased from the Asociación Banco 
Argentino de Células, were routinely cultured in Dulbecco's 
modified Eagle's medium (DMEM) (Hyclone) with 4 mM 
L-glutamine, 4.5 g/l glucose, 1x10-6 M biotin and 0.11 g/l sodium 
pyruvate, and supplemented with 10% fetal bovine serum (FBS) 
(Gen SA, Bs. As.) plus antibiotics (Gibco, Life Technologies).
RNA extraction, RT-PCR and primer sets. Total cellular 
RNA was isolated by the Chomczynski and Sacchi method 
(22). Briefly, 1x107 3T3-L1 cells were harvested during the 
proliferative phase. Cell monolayers were washed twice with 
Ca2+ and Mg2+ free-cold phosphate buffered saline (PBS), 
and cells were collected with a rubber policeman in 1 ml/dish 
of D Solution [4 M guanidinium thiocyanate, 25 mM sodium 
citrate (pH 7), 0.5% w/v sarkosyl, 0.1 M β-mercaptoethanol], 
finishing lysis by passaging cells 5 times using a 21G needle. 
Considering a total final volume of 10 ml, 1 ml 2 M sodium 
acetate (pH 4), 10 ml water-saturated phenol (pH 5) and 
2 ml 49:1 chloroform/isoamyl alcohol were added, mixing 
thoroughly each time, with vortex agitation twice for 30 sec 
with an intermediate rest time of 1 min on ice. After 15 min 
of incubation on ice, the suspension was centrifuged at 
10,000 rpm at 4˚C for 20 min and the aqueous phase was 
transferred to a fresh tube and mixed with an equal volume of 
isopropyl alcohol. Samples were maintained for at least 3 h at 
-20˚C. After another centrifugation at 10,000 rpm at 4˚C for 
20 min, the supernatant was discarded and the RNA pellet 
was dissolved in 2 ml D Solution. RNA was again precipi-
tated with 1 ml isopropyl alcohol and maintained at -20˚C for 
at least 3 h. Following centrifugation at 10,000 rpm at 4˚C for 
20 min, the supernatant was discarded and the RNA pellet 
was washed with 70% ethanol, air-dried and resuspended 
in 100 µl RNAse-free water. RNA purity and concentration 
were evaluated spectrophotometrically (ADN/ARN absor-
bance, 1.8) and visually (in 1% agarose gels, stained with 
ethidium bromide, presence of 2 bands corresponding to 18S 
and 28S).
RT-PCR. The Promega Corp. System and a Mastercycler 
gradient thermocycler (Eppendorf, Hauppauge, NY, USA) 
were used to transcribe and amplify RNA. Briefly, RNA was 
incubated for 10 min at 70˚C to destabilize secondary struc-
tures and after a brief centrifugation it was rapidly cooled on 
ice. cDNA was obtained through reverse transcription (RT) 
in the following mix reaction: 5 mM MgCl2, buffer [10 mM 
Tris-HCl (pH 9.0), 50 mM KCl and 0.1% v/v Triton X-100], 
1 mM dNTP, 15 U/µg AMV reverse transcriptase, Rnasin® 
1 U/µl recombinant ribonuclease inhibitor, 50 ng/µl RNA and 
0.025 µg/µl random ‘primers’, with a pre-incubation step at 
room temperature followed by an incubation step at 42˚C for 
60 min. The sample was heated at 95˚C for 5 min to inactivate 
the AMV enzyme and then maintained on ice until use.
For PCR reactions, 20 ng cDNA previously transcribed, 
2-4 mM MgCl2, Buffer [10 mM Tris-HCl (pH 9.0), 50 mM 
KCl and 0.1% v/v Triton X-100], 200 µM dNTP, 15 U/µg Taq 
DNA polymerase and 0.5 µM (5' and 3') specific primers were 
used.
Samples were subjected to a single pre-denaturing cycle at 
94˚C for 5 min, followed by 30 cycles, each with a denaturing 
step at 94˚C for 30 sec, annealing at a specific temperature 
for each set of primers for 1 min and elongation at 72˚C for 
2 min, ending with a final elongation at 72˚C for 7 min and 
polymerase inactivation at 4˚C.
Primers. All sets of primers, with the exception of those 
for EGFR/erbB1 (Genosys, Canada), were acquired from 
Tecnolab SA, Argentina (for Operon, a Qiagen company) and 
desalted in a 50-nM scale (Table I). 
After amplification, specific fragments were separated and 
visualized in 1% agarose (Seakem ME) gels in buffer TBE 
[0.9 M Tris, 0.9 M boric acid and 20 mM EDTA (pH 7.8)] 
stained with ethidium bromide, at 70 V for 30 min. 
Restriction enzyme analysis. PCR product specificity was 
analyzed by endonuclesase restriction, with enzymes that 
cleave DNA inside specific sequences, generally palindromes. 
Basically, we searched for enzymes restriction sites in the 
amplified segment sequence and then, which one of them cut 
only once and finally, between these ones, which ones produce 
segments of a proper size to be observed in an agarose gel. 
Enzymatic digestion was performed using the reaction mixture: 
5 µl PCR product, 0.5 µl endonuclease, 1 µl buffer and 3.5 µl 
water. The reaction was incubated at 37˚C for 3 h and stopped 
with loading buffer [0.03% bromophenol blue, 0.03% cylene 
cyanol, 0.4% orange G, 15% Ficoll 400, 10 mM Tris-HCl 
(pH 7.5) and 50 mM EDTA]. The PCR products digested in this 
manner were analyzed together with the undigested fragments 
in agarose gels to visualize the reaction and check for cleavage 
efficiency according to the expected length (pb).
RsaI. Pseudomonas sphaeroides (Biolabs). 5'…GT▼AC…3', 
3'…CA▲TG…5'; Eco RI 5'…G▼AATTC…3', 3'…
CTTAA▲G…5'.
Results
erbB2 mRNA expression in 3T3-L1 cells. ErbB2 expression 
in a variety of human cancers, such as breast, ovary and 
lung cancer, has been extensively documented in terms of 
overexpression and amplification. However, erbB2 expression 
or the presence of ErbB in general have not been frequently 
described in fibroblasts, with the exception of decidua cells 
(23,24), mammary gland fibroblasts (25) and the Rat-1 cell 
line (26). Therefore, erbB expression was evaluated in the 
3T3-L1 model of adipogenic differentiation. 
Of note is that when these experiments were first started, 
the complete murine erbB2 sequence was unknown (at 
present, the complete v-erbB2 murine sequence BC046811 
is known to present an 83-87% homology with the human 
c-erbB2). Only a partial sequence was available (2,083 bp) 
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corresponding to the 3' end of human c-erbB2 (4,473 bp; 
87% homology). The primers were designed, based on this 
sequence, to detect erbB2 mRNA expression in 3T3-L1 cells 
through RT-PCR. This erbB2 mRNA portion has the lowest 
homology with EGFR (<20%). The primers included wobble 
(X/Y) positions to increase possibilities of amplifying the 
erbB2 sequence in mouse. This set of primers provided an 
RT-PCR product of ~300 bp (Fig. 1A), which was confirmed 
as erbB2 by Rsa cleavage (328 bp = 237 + 91 bp).
Additionally, we amplified a larger segment using this 
forward primer designed against the human sequence (10), 
whereas the primer that had previously been designed against 
the mouse sequence was used as the reverse primer. This combi-
nation of primers yielded a segment of ~1,900 bp (Fig. 1B), 
confirmed as erbB2 by EcoRI cleavage (1,917 bp = 1,269 + 648 
bp). 
To the best of our knowledge, this is the first observation of 
erbB2 mRNA expression in the 3T3-L1 cell line in the literature.
Table I. List of PCR primers used.
Receptor Genbank accession no. Primer Sequence (5' to 3')
erbB2 Human (31997) X03363 F: CT GGC TCC GAT GT(A/G) TTT 3GAT GG
 3,416→3,437
 Mouse (200711980) AK031099
 1,036→1,057
 Human 3,723←3,744 R: (A/G)GC ACC CCC AAA GGC AAA AAC G
 Mouse 1,343←1,364
HER2-ECD  F: AGG GAG TAT GTG A(A/G)(G/T) G(C/G)C
  1,828→1,845
  R: CCT GAA AGA AAG TCC TCC
Herstatin (10181232) AF177761  F: TG AGC ACC ATG GAG CTG GC
  167→185
  R: TC CGG CA(A/G) AAA TGC CAG GCT CC
  1,289←1,310
EGFR Mouse (488830) X78987 F: CC AAA TGT GAT CCA AGC TGT CC
  622→643
  R: TCC GAG GAG CAT AAA GGA TTG 
  1,577←1,597
erbB3 Mouse (25071684) XM_125954.4 F: CTG GGC GTG TCT ACA TAA GTG C 
  11→32
  R: A TGG CAG GAG AAG CAA TGA GCC 
  297←318
erbB4 Rat (4176734) AF041838 F: CAT CTA CAC ATC CAG AAC A
 Mouse (23622469) XM_136679 3,133→3,150
  R: AAA CAT CTC AGC CGT TGC A 
  3,321←3,339
Figure 1. Wild-type erbB2 expression in 3T3-L1 cells. (A) Total RNA was extracted from 3T3-L1 proliferating cells. After obtaining cDNA by reverse 
transcription, erbB2 was amplified with specific primers through PCR. RsaI enzymatic digestion of the complete segment (328 bp) yielded two fragments of 
the expected size. (B) Amplification with a human forward primer and a murine reverse primer of a larger segment (1,917 bp) and EcoRI-specific cleavage 
confirmed fragment identity as erbB2. PCR products were analyzed in 1% agarose gels plus ethidium bromide in TBE buffer. Specificity of PCR products was 
analyzed by endonuclease cleavage. Fragments digested in this manner were run together with complete fragments to verify cleavage efficiency according to 
expected and obtained sizes in bp. Molecular weight markers (MW) Low DNA Mass Ladder.
  A   B
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erbB2 splicing variants in 3T3-L1 cells
HER2-ECD expression in 3T3-L1 cells. We evaluated 
the possibility that 3T3-L1 cells express an erbB2 variant 
that provides a truncated protein of 100 kDa, the human 
erbB2-extracellular domain (HER2-ECD), which has an 
antiproliferative activity in tumor cells with a tendency to 
disappear in more advanced or aggressive tumor phenotypes. 
This splicing variant is derived from a 2.3 kb-mRNA, almost 
half the wild-type length, which retains the four extracellular 
subdomains, but loses the transmembrane and the cytoplasmic 
domains (from the 633 aa it embraces, the last 25 from the 3' 
end differ from the wild-type).
Another set of primers (Table I) (10) was used to identify 
this alternative splice variant. As shown in Fig. 2A a specific 
fragment was positively amplified with the expected size for 
HER2-ECD in 3T3-L1 cells, by the lack of any other bands. 
HER2-ECD expression was low in comparison with that 
shown by breast carcinoma.
Herstatin expression in 3T3-L1 cells. Herstatin 
(AF177761) is a 68-kDa protein described as an erbB2 auto-
inhibitor, which, upon binding to the receptor itself, interferes 
with dimer formation and reduces receptor tyrosine phosphor-
ylation (19). It is produced by an alternative truncated mRNA 
whose protein contains the first 340 aa of the erbB2 protein 
(ECD subdomains I and II) fused to a unique stretch of 79 aa 
that arises from the insertion of an intronic sequence.
Using the primers previously described (Materials and 
methods and Table I), we obtained an RT-PCR product of 
the expected length (1,143 bp) positively amplified in 3T3-L1 
cells as in epithelial cells from murine breast cancer (Fig. 2B), 
although it appears evident that the expression of each one is 
relatively low. 
As for HER2-ECD, the meaning or function of a low 
herstatin expression in 3T3-L1 cells, as in any other normal 
cells, would require more attention. It is possible that the 
expression of these erbB2 variants as alternative mechanisms 
to control cell proliferation and/or erbB2 activity are not 
required under physiological circumstances, although they are 
ready to be activated in case of need.
EGFR/erbB1 expression in 3T3-L1 cells. The proliferative 
dependence of 3T3-L1 cells on EGF presence in the culture 
medium was described at the beginning of this model charac-
terization (27), whereas its receptor expression was described 
at the protein level (28). EGFR expression in adipocytes was 
demonstrated in in vivo studies (29) as well as in 3T3-L1 
cell line cultures (28,30,31). In this study, EGFR expression 
was confirmed by RT-PCR in our 3T3-L1 cell system using 
specific primers designed in our lab from the complete murine 
sequence (gi: 488830, X78987) (Fig. 3).
erbB3 expression in 3T3-L1 cells. A set of primers 
matching the 5' end of this cDNA was designed from the 
4,524 bp erbB3 sequence found in the NCBI database (gi: 
25071684, XM_125954.4). These primers amplified several 
fragments by RT-PCR in 3T3-L1 cells, and one of these frag-
ments had the expected size (308 bp) for erbB3. cDNA samples 
from a murine breast cancer and rat normal mammary acines 
were used as positive controls (Fig. 4A). The identity of erbB3 
was confirmed by RsaI cleavage (Fig. 4B), which yielded two 
fragments of 104 and 204 bp. This is the first demonstration of 
erbB3 expression in preadipocytes in vivo as well as in vitro.
erbB4 expression in 3T3-L1 cells. Since the murine erbB4 
sequence was incomplete (gi: 23622469, XM_136679), a 
combination of primers designed against the rat sequence were 
used (32) (gi: 4176734, AF041838). Homology of 95% was 
observed between the rat 4,060 bp and the mouse 1,284 bp. 
Figure 2. erbB2 splicing variant expression in 3T3-L1 cells. (A) Using 
oligonucleotides designed to amplify a human truncated version of erbB2 
(lacking cytoplasmic domain), HER2-ECD expression in 3T3-L1 cells was 
obtained (expected product size, 290 bp). It is evident that its expression is 
lower than that of a murine breast carcinoma (CaMa). It was used as the 
molecular weight marker (MW) Low DNA Mass Ladder. Subsequently, an 
evaluation of the mass bands was performed. While the full PCR reaction 
volume was loaded in two wells for 3T3-L1 cells, only half was loaded for 
CaMa (approximate ratio 3T3-L1/CaMa, 1/4). (B) Herstatin, another erbB2 
soluble truncated variant, was amplified from the 3T3-L1 cell cDNA. Breast 
cancer cells (CaMa) as well as 3T3-L1 cells exhibit a very low fragment 
expression (1,143 bp).
Figure 3. EGFR expression in 3T3-L1 cells. Total RNA from 3T3-L1 cells 
underwent RT-PCR for EGFR mRNA. The product has the expected size 
(975 bp). Molecular weight markers (MW) Low DNA Mass Ladder.
  A
  B
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Homology was absolute (100%) between the primer binding 
regions. On the other hand, inside the region to be amplified 
there are only seven mismatches and none in the binding sites 
of the primers. Although we were able to amplify a specific 
fragment of the expected size (206 bp) in rat mammary acines 
by RT-PCR due to the satisfactory RsaI digestion (111 + 95 bp), 
none of the 3T3-L1 bands were erbB4 (Fig. 5).
Discussion
Since our concern was to evaluate the expression of not 
only the wild-type but also other mRNA variants of erbB2 
in 3T3-L1 cells, we designed a set of primers and adapted 
and modified other primer sets obtained from the literature 
to achieve this target, based on a mouse sequence of only 
2,083 bp with an 87% homology with its human counterpart 
(Fig. 1A). Primers recognized identical cDNA regions in both 
species with one base exception, allowing us to prepare wobble 
oligomers, which carry the murine or human base in that 
position in equal parts. In this manner, segment amplification 
was ensured despite this minor discrepancy. The amplified 
sequence was shown to match erbB2. Additionally, we were 
able to amplify a larger fragment using a 5' human (10) and 
a 3' murine primer that were previously used (Fig. 1B). In 
each case, enzymatic digestion allowed us to obtain a posi-
tive match with erbB2 mRNA, since cleavage sites remained 
intact in the two species. This result shows the high degree of 
homology that murine and human erbB2 share.
HER2-ECD has been described as one of these splicing 
variants (11). HER2-ECD is expressed in numerous tumor 
cell lines that also express erbB2/HER2, and its relative 
abundance is variable. In gastric cancer cells (MKN7) it 
is higher than, in decreasing order, ovarian (SK-OV-3) and 
breast cancer cells (BT-474 y SK-BR-3). HER2-ECD has also 
been observed in the sera of HER2-carrying tumor patients 
(33), in ganglia micrometastasis, in bone marrow (34) and in 
conditioned media from cell lines mostly produced by limited 
proteolysis as opposed to alternative splicing. However, 
HER2-ECD remained in the cytoplasm in the latter case. 
HER2-ECD function in tumor cells is not currently well 
understood. The role of HER2-ECD mRNA loss in advanced 
Figure 4. erbB3 expression in 3T3-L1 cells. (A) erbB3 was amplified by 
RT-PCR in 3T3-L1 cells, using murine breast carcinoma cells (CaMa) and 
normal rat mammary acines (AcMa) as positive controls. (B) Since ampli-
fication produced several fragments besides the expected one (308 bp), its 
specificity was examined by RsaI cleavage (104 + 204 bp). Positive control: 
normal rat mammary acines (AcMa).
Figure 5. erbB4 expression in 3T3-L1 cells. (A) From total cDNA of 3T3-L1 
cells, we attempted to amplify erbB4, using murine breast carcinoma cells 
(CaMa) and normal rat mammary acines (AcMa) as positive controls. The 
three sources produced several fragments. (B) 3T3-L1 band specificity was 
studied by RsaI cleavage, but none were revealed to be erbB4, since the 
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gastric tumors indicates a potential role for erbB2 truncated 
forms in controlling tumor proliferation in humans. It is also 
likely that HER2-ECD function depends on the tumoral type 
under study, since high levels in the sera of oncologic patients 
inversely correlate with chemotherapy results (33). Since 
this variant is devoid of the kinase domain and is therefore 
unable to transduce intracellular signals, some authors have 
proposed that it may aggregate with complete receptors of 
the erbB family to modulate their activity (34), in a similar 
fashion to the inactivation that follows normal and truncated 
EGFR interaction (35,36). Although it was possible to amplify 
HER2-ECD in 3T3-L1 cells with specific primers (Fig. 2A), 
its expression was found to be lower than that of a breast 
carcinoma. Despite this, it is possible that future studies may 
demonstrate the existence of erbB2 variants in mice and their 
possible function in adipogenesis, whether similar or not 
to their human counterparts, since no previous studies are 
currently available on this subject.
Herstatin, another erbB2 splicing variant, is produced after 
a truncated mRNA (2.6 kb) that codifies only for the first two 
extracellular subdomains (19). Herstatin is present in human 
fetal kidney and liver and in the non-tumorigenic cell lines 
IOSEVAN (epithelial ovarian cells) and HBL-100 (mammary 
cells), while its expression is lower in cells where erbB2 is 
amplified, such as BT474 or SKOV-3 (19). In this study, it was 
possible to obtain the expected size fragment in 3T3-L1 cells 
using primers described by Doherty et al (19), although its 
expression was found to be extremely low, not only in these 
cells, but also in breast carcinoma ones (Fig. 2B). Therefore, 
more studies are required to assess the expression of erbB2 
variants in 3T3-L1 cells and any connection that may exist with 
adipogenic differentiation. 
ErbB3 is another member of this family of receptors, 
occasionally referred to as ‘the dumb’, as well as erbB2, ‘the 
deaf’. This is due to the fact that erbB3 has a deficient kinase 
that prevents it from transducing an intracellular signal, and 
because erbB2 has no known ligand to date; hence, it is unable 
to ‘listen’ (37). For these reasons, the receptors are compelled to 
dimerize with a different dimerization partner, unless in case of 
a receptor overexpression. The erbB2-erbB3 heterodimer is able 
to transduce one of the more potent mitogenic signals in this 
family and to cause neoplastic transformation (38). Therefore, it 
was crucial for our differentiation model to test erbB3 mRNA 
existence in 3T3-L1 cells. erbB3 also has different isoforms, of 
which p85-serbB3 (soluble) is capable of inhibiting heregulin-
mediated erbB2, erbB3 and erbB4 activation (39,40). However, 
in this study, only the wild-type receptor was investigated 
[erbB3 expression in 3T3-L1 cells at the protein level, previ-
ously published (20)]. Based on the erbB3 murine sequence, we 
designed a pair of primers corresponding to mRNA 5' end that 
amplified a fragment of the expected size (308 pb) plus two more 
fragments of variable size (Fig. 4A). A murine breast carcinoma 
and normal rat mammary acines were used as a positive control, 
since they present high erbB3 expression (25,41). The fragment 
was shown to be specific by restriction analysis (Fig. 4B). The 
observation of erbB3 expression in 3T3-L1 or adipocytic cells 
for the first time in the literature indicates a possibility for erbB3 
function inside the adipogenic process.
ErbB4 is the last member of this family to be described. 
It mediates neuregulins and other EGF-related growth factor 
responses. It has a fundamental role in the regulation of cardiac, 
neural and mammary development and, as with erbB2, it is 
also related to neoplastic transformation and cardiac disorders. 
Chemotaxis and cellular survival are regulated by the expres-
sion of erbB4 isoforms that differ in their ability to couple 
PI3-K signaling (42). Four isoforms have been identified as 
structurally and functionally different from erbB4, which are 
sensitive or resistant to the proteolytic cleavage that releases a 
soluble extracellular domain and which are able or unable to 
activate MAPK or PI3-K/Akt pathways, explaining the different 
cellular outputs transduced through each of them (43).
erbB4 expression has not previously been investigated before 
in this model of adipogenic differentiation. The murine sequence 
was not complete, resulting in rat sequence-based designed 
primers being used (32). Homology of 95% was observed 
between the 4,060 bp rat sequence and the 1,084 bp mouse 
sequence. Homology was absolute (100%) in the binding region 
of the primers. erbB4 was positively amplified in rat mammary 
acines, but none of the bands were revealed to be erbB4 in 
3T3-L1 cells (Fig. 5). We have already discussed the presence 
of receptor isoforms at the protein level in a previous study (20).
Supporting these results, it is notable that the full pres-
ence of all members of the erbB family would be redundant 
in a single cell type, particularly if normal. Usually, a cell 
expresses one or two erbBs, and no more than three. For 
example, NIH-3T3 cells lack endogenous detectable levels of 
EGFR, erbB3 and erbB4 and exhibit only extremely low levels 
of erbB2 (3), while only EGFR and erbB2 are present in Rat-1 
fibroblasts (26). Therefore, the mRNA expression of erbB2, 
erbB1/EGFR and erbB3 was confirmed in 3T3-L1 cells in this 
study.
Expression of erbB2 at the protein level in 3T3-L1 cells 
(20) and its involvement in the proliferation/differentiation 
processes of these cells were previously observed (21). The 
present study completes our understanding of the expression, 
modulation and activation of the erbB receptors in the 3T3-L1 
cell line and poses new questions regarding possible roles for 
erbB soluble forms in this adipogenic model.
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